Healthcare
Live Price
Offline$0.69
+5.99% today
1Y Change
+180.49%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TerrAscend Corp. (TSNDF) is a Healthcare stock with a market cap of $230.00M and listed on OTC. The stock last traded around $0.69 and up 180.5% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -40.9%, EPS growth of -3.6%, a dividend yield of 0.0%. What stands out right now is revenue -40.9%, EPS -3.6%, free cash flow -53.4% with operating margin 15.4% and ROIC -186.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TSNDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSNDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TSNDF Max Drawdown
-66.96%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TSNDF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$194.2M
-21.6% YoY
FY Net Income
$12.6M
+104.2% YoY
Free Cash Flow
-$88.9M
-1.1% YoY
Revenue Growth
-40.9%
EPS Growth
-3.6%
Gross Margin
51.3%
Net Margin
-32.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 261M | 441M | 317M | 248M | 194M |
| Gross Profit | 136M | 216M | 160M | 102M | 116M |
| Operating Income | 42M | -25M | -23M | -336M | 23M |
| EBITDA | 63M | 50M | -1M | -247M | 48M |
| Net Income | -86M | -80M | -91M | -304M | 13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 37M | 26M | 22M | 36M | 101M |
| Total Assets | 557M | 607M | 667M | 951M | 582M |
| Total Liabilities | 458M | 430M | 426M | 511M | 450M |
| Shareholder Equity | 97M | 177M | 320M | 432M | 224M |
| Total Debt | 256M | 246M | 256M | 235M | 211M |
| Net Debt | 219M | 36M | 233M | 298M | 174M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
38M
-15.3% YoY
Capital Expenditures
50M
+7.6% YoY
Free Cash Flow
89M
-1.1% YoY
Key ratios
Gross Margin
51.3%
Operating Margin
15.4%
Net Margin
-32.1%
ROE
-72.8%
Debt / Equity
2.64x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.